CareDx, Inc beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +0.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.17 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | not reported | $0.05 | not reported | not reported | Q1 FY26 call |
| Q4 FY25 | $0.00 | $-0.08 | not reported | Miss | |
| Q3 FY25 | not reported | $0.03 | not reported | not reported | |
| Q2 FY25 | $-0.11 | $-0.16 | -45.5% | Miss | |
| Q1 FY25 | $-0.21 | $-0.19 | +9.5% | Beat | |
| Q4 FY24 | not reported | $1.51 | not reported | not reported | |
| Q3 FY24 | $-0.25 | $-0.14 | +44.0% | Beat | |
| Q2 FY24 | not reported | $-0.03 | not reported | not reported | |
| Q1 FY24 | $-0.46 | $-0.28 | +39.1% | Beat | |
| Q4 FY23 | not reported | $-2.21 | not reported | not reported | |
| Q3 FY23 | $-0.67 | $-0.43 | +35.8% | Beat |
Back to CDNA overview · CDNA holders · CDNA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.